Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street

Insiders have been trading these 5 stocks: ((GTLB)), ((ALT)), ((LNG)), ((PACB)) and ((HTGC)). Here is a breakdown of their recent trades and their value.

Director Susan Bostrom’s move to sell 32,500 shares of Gitlab stock, a transaction valued at $661,700, has drawn attention from traders watching insider sentiment. While a single sale does not define a company’s trajectory, such a sizable divestment can prompt investors to reassess short‑term expectations for Gitlab’s growth and valuation.

Altimmune has seen a wave of insider confidence, as CFO Gregory Weaver bought 10,000 shares for $31,400 while President & CEO Jerome Benedict Durso acquired 15,000 shares worth $47,100. Together these purchases, totaling 25,000 shares and $78,500, signal a strong internal vote of confidence in Altimmune’s prospects.

Cheniere Energy has been the stage for heavy insider selling, led by Director Andrea Botta offloading 5,000 shares for $1,482,350. Director Anatol Feygin sold 40,432 shares for $11,764,447, GC & Corporate Secretary Sean Markowitz sold 22,246 shares for $6,473,077, and EVP & CFO Zach Davis sold 29,000 shares for $8,700,000, marking a massive multi‑executive cash‑out.

Pacific Biosciences saw CFO James R. Gibson sell 88,185 shares in a transaction valued at $120,813, sparking questions about the timing and rationale behind the move. Though the dollar figure appears modest relative to the volume, investors often scrutinize such insider activity for potential signals on future performance.

At Hercules Capital, Inc., insiders are clearly buying, with Director Thomas Fallon purchasing 7,300 shares for $104,390 as a notable vote of confidence. Director Robert Badavas added 3,658 shares for $52,492, and Director Paramjeet K Randhawa bought 2,926 shares worth $41,988, collectively reinforcing a bullish insider stance on Hercules Capital’s outlook.